Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 19/20 | 0.48 |
| ▸ | KCNJ11 | Q14654 | 19/20 | 0.48 |
| ▸ | ABCC8 | Q09428 | 17/20 | 0.48 |
| ▸ | KCNJ8 | Q15842 | 17/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644769 | 0.94 | ABCC9 (0.56) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6645396 | 0.89 | ABCC9 (0.61) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6644766 | 0.88 | ABCC9 (0.56) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6647529 | 0.87 | ABCC9 (0.44) | ABCC9KCNJ11ABCC8KCNJ8BRD4 | |
| SCHEMBL6647856 | 0.83 | ABCC9 (0.45) | ABCC9KCNJ11ABCC8KCNJ8BRD4 | |
| SCHEMBL6641737 | 0.83 | ABCC9 (0.62) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6644997 | 0.82 | ABCC9 (0.49) | ABCC9KCNJ11ABCC8KCNJ8BRD4 | |
| SCHEMBL6642676 | 0.81 | ABCC9 (0.46) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6852181 | 0.80 | ABCC9 (0.48) | ABCC9KCNJ11ABCC8KCNJ8BRD4 | |
| SCHEMBL6642946 | 0.79 | ABCC9 (0.49) | ABCC9KCNJ11ABCC8KCNJ8BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780872-B2 | ASTHMA; ANTIEPILEPTIC AGENTS; SEXUAL DISORDERS | ABBOTT LABORATORIES | 2004-08-24 | — | — | US | disclosed |
| EP-1259510-B1 | TRICYCLIC DIHYDROPYRAZOLONE AND TRICYCLIC DIHYDROISOXAZOLONE POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030171394-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | DRIZIN IRENE (US) | 2003-09-11 | — | — | US | disclosed |
| US-6538004-B2 | Potassium channel modulators relax smooth muscle cells and inhibit bladder contractions; treating nervous, eating, cardiovascular, gastrointestinal, and sexual disorders | ABBOTT LABORATORIES | 2003-03-25 | — | — | US | disclosed |
| EP-1259510-A2 | TRICYCLIC DIHYDROPYRAZOLONE AND TRICYCLIC DIHYDROISOXAZOLONE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020007059-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | ABBOTT LABORATORIES | 2002-01-17 | — | — | US | disclosed |
| WO-2001066544-A2 | TRICYCLIC DIHYDROPYRAZOLONE AND TRICYCLIC DIHYDROISOXAZOLONE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171394-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | KCNJ2, KCNH1, KCNJ1 | ABCC9 741/4885KCNJ11 4/4885ABCC8 700/4885 |
| US-20020007059-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | KCNJ2, KCNH1, KCNJ1 | ABCC9 741/4885KCNJ11 4/4885ABCC8 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.